Education
About Us
Working with TipRanks
Follow Us
Madrigal (MDGL)
NASDAQ:MDGL
MDGL Stock Chart & Stats
$435.62
-$1.78(-0.55%)
At close: 4:00 PM EST
$435.62
-$1.78(-0.55%)
Day’s Range― - ―
52-Week Range$265.00 - $615.00
Previous CloseN/A
Volume47.78K
Average Volume (3M)356.19K
Market Cap
$9.99B
Enterprise Value$10.05B
Total Cash (Recent Filing)$983.56M
Total Debt (Recent Filing)$354.36M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 12, 2026EPS Estimate
-3.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.57
Shares Outstanding22,939,968
10 Day Avg. Volume448,910
30 Day Avg. Volume356,186
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)21.68
Price to Sales (P/S)13.63
P/FCF Ratio-68.75
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue10.49
Enterprise Value/Gross Profit11.14
Enterprise Value/Ebitda-38.00
Forecast
1Y Price Target
$694.90Price Target Upside59.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.55
Revenue Forecast (FY)$1.48B
Bulls Say, Bears Say
Bulls Say
Commercial Launch MomentumRobust commercial uptake of Rezdiffra, with accelerating patient adoption and revenue growth, indicates sustained launch momentum and meaningful expansion of the treated population.
Payer Access And Prescriber AdoptionNew payer contracts granting first-line access without step edits, alongside broad prescriber use, should improve patient access and accelerate therapy adoption.
Pipeline Expansion And Combination StrategyExclusive rights to an oral DGAT-2 inhibitor and planned drug–drug interaction and combination trials with Rezdiffra expand development options and could yield additive clinical benefits.
Bears Say
Competitive LandscapeAn expanding competitive set, including lower-cost GLP‑1 therapies and more potent emerging drug classes, could erode market share and weaken pricing power.
Pricing And ReimbursementsElevated gross-to-net adjustments and deeper commercial discounts from contracts may reduce reported sales and compress profit margins.
Profitability And Cash ResourcesRising operating and research expenses, combined with licensing charges, can widen losses and strain cash resources, pressuring near-term profitability.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal’s price range in the past 12 months?
Madrigal lowest stock price was $265.00 and its highest was $615.00 in the past 12 months.
What is Madrigal’s market cap?
Madrigal’s market cap is $9.99B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is May 12, 2026 which is in 70 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on Feb 19, 2026. The company reported -$2.57 earnings per share for the quarter, missing the consensus estimate of -$0.895 by -$1.675.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -3.88.
How many shares outstanding does Madrigal have?
Madrigal has 22,939,968 shares outstanding.
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -$2.57 in its last earnings report, missing expectations of -$0.895. Following the earnings report the stock price went down -11.113%.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in MDGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Madrigal Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$694.90 (59.52% Upside)
$694.90 (59.52% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 245.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.64%
12-Months-Change
Fundamentals
Return on Equity
-42.49%
Trailing 12-Months
Asset Growth
20.85%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
MDGL Company Deck
MDGL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong, high-performing commercial launch (nearly $1B first-year sales), accelerating patient uptake, a sizable and fast-growing U.S. addressable market, a cash-strong balance sheet, and rapid pipeline expansion anchored to Rezdiffra (patent protection to 2045). Key near-term headwinds include expected gross-to-net deterioration into the high 30% range in 2026 (reducing net revenue), Q1 seasonality and contracting timing effects, higher R&D/SG&A from business-development and launch investments, and limited near-term international revenue. Management portrayed confidence in continued robust growth, disciplined R&D/combination strategy, and an adaptive approach to payer partnerships and persistence initiatives.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$694.90
▲(59.52% Upside)
Technical Analysis
Exelixis
―
Ionis Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Roivant Sciences
―
Ownership Overview
Currently, No data available
---